Archive | Thought Leadership RSS feed for this section

Mvasi by Amgen is the First FDA Approved Cancer Biosimilar

FDA Approves the First Cancer Biosimilar Mvasi by Amgen is Hitting the US Market   Yesterday the FDA announced that Amgens biosimilar to Avastin, known as Mvasi (bevacizumab-awwb) was approved for five different types of cancer: Non-squamous non-small cell lung cancer (NSCLC) – in combination with chemotherapy Metastatic colorectal cancer (mCRC) – in combination with chemotherapy Glioblastoma Metastatic renal […]

Kelly Scientific Winner of Network Kildare Business Award

Deirdre Kelly PhD, was announced Emerging Business Woman of the Year 2017 by Network Kildare at Palmerstown House Estate last Friday evening.   Presented with the award by Minister of Jobs, Enterprise and Innovation, Mary Mitchell-O’Connor and President of Network Kildare Pauline Forde, Deirdre announced ‘it is a privilege and honor to receive such a prestigious […]

Regenerative Medicine Market to Hit $53 billion by 2021 – How Will the Trump Administration Affect its Growth?

Leading market analysts at Kelly Scientific indicate that the current regenerative medicine market is worth $18.9 billion globally, and will hit over $53 billion by 2021. Managing Director, Deirdre Kelly PhD announced, ‘the stem cell and tissue engineering sectors are currently driving this market at a strong CAGR of 23.3% over the next five years, […]

Interview With The Expert: Jennifer Rock on the Aesthetics Industry

Recently I had the pleasure of connecting with Jennifer Rock, aka the skin nerd on all things cutting-edge in the medical aesthetic industry. Jennifer has lectured throughout the UK, the USA, Ireland and Mainland Europe, alongside many surgeons, dentists and experts in their own respective field. Her insights into what the cosmetic end user really wants […]

Medical Aesthetic Market will Hit $69,786 million in 2021

Kelly Scientific analysis indicates that the current medical aesthetic industry is worth $52,405 million for both service and product revenue. Over the next five years a CAGR of 5.5% is expected and the market will hit $69,786 million in 2021. Currently, invasive aesthetic procedures generated revenues of $27,843.5 million in 2015. Kelly Scientific analysis indicate […]

Stem Cells and High Throughput Screening

By Orla Dunne   Big pharma and biotech have put significant investment into developing high throughput screening (HTS) technologies to improve the efficiency of early drug discovery. Immortalised cells, sourced from tumours or from transformed oncogenes, are readily engineered to express target proteins and reporters in a fashion that minimizes background noise, thus making them a popular […]

Meet Deirdre at MAP 2015 Molecular Analysis for Personalised Therapy

The first Molecular Analysis for Personalised therapy (MAP) meeting will be held in Paris, Oct 23/24 2015 and is organised by UNICANCER, ESMO and Cancer Research UK. I’m looking forward to hearing expert opinions on the clinical interpretation of molecular tests for metastatic cancers and specifically the following talks: Beyond driver identification: what can we […]